Drug Profile
MK 3134
Alternative Names: MK-3134Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antidementias; Sleep disorder therapies
- Mechanism of Action Histamine H3 receptor inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Dementia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Dementia(In volunteers) in Belgium (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Dementia(In volunteers) in United Kingdom (PO, Tablet)